• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

A basic study of Cancer vaccine therapy using genetically modified iPSDCs targeting for a Cancer Stem Cell

Research Project

Project/Area Number 15H06553
Research Category

Grant-in-Aid for Research Activity Start-up

Allocation TypeSingle-year Grants
Research Field Digestive surgery
Research InstitutionWakayama Medical University

Principal Investigator

Iwamoto Hiromitsu  和歌山県立医科大学, 医学部, 学内助教 (60756592)

Project Period (FY) 2015-08-28 – 2017-03-31
Project Status Completed (Fiscal Year 2016)
Budget Amount *help
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords腫瘍免疫 / iPSDCs / 癌ワクチン / 再生医療 / 癌幹細胞 / iPS細胞 / 腫瘍抗原遺伝子 / 樹状細胞 / 免疫治療
Outline of Final Research Achievements

We induced Yamanaka four factors into healthy human peripheral blood mononuclear cells (PBMCs) with Sendai virus vector, and iPS cells were established. In this case, it was carried out according to iPS cells derived from fibroblasts which we have carried out in our department. We induced differentiation into iPSDCs by various methods. As a result, it became clear that it is most efficient to induce differentiation with cytokine cocktail. It was found that iPSDCs obtained thereby had sufficient function as antigen presenting cells.
Next, the CEA gene was introduced into this iPSDCs and its antitumor effect was evaluated with a virtual antigen and a human cancer cell line with a Cr release assay to confirm tumor antigen specific antitumor effect.

Report

(3 results)
  • 2016 Annual Research Report   Final Research Report ( PDF )
  • 2015 Annual Research Report
  • Research Products

    (7 results)

All 2017 2016 2015

All Journal Article (1 results) (of which Peer Reviewed: 1 results) Presentation (6 results) (of which Int'l Joint Research: 1 results)

  • [Journal Article] CEA遺伝子導入ヒトiPS細胞由来樹状細胞(iPSDCs)を用いた癌ワクチン療法の検討2016

    • Author(s)
      北谷純也、岩本博光
    • Journal Title

      癌と化学療法

      Volume: 43 Pages: 1071-1073

    • Related Report
      2016 Annual Research Report
    • Peer Reviewed
  • [Presentation] CEA遺伝子導入iPS細胞由来樹状細胞を用いた癌ワクチン療法の検討2017

    • Author(s)
      北谷純也、岩本博光
    • Organizer
      第16回日本再生医療学会総会
    • Place of Presentation
      仙台国際センター
    • Year and Date
      2017-03-07
    • Related Report
      2016 Annual Research Report
  • [Presentation] 担癌患者のヒトiPS細胞由来樹状細胞(iPSDCs)を用いた新規免疫療法の確立2017

    • Author(s)
      田端宏尭、岩本博光
    • Organizer
      第16回日本再生医療学会総会
    • Place of Presentation
      仙台国際センター
    • Year and Date
      2017-03-07
    • Related Report
      2016 Annual Research Report
  • [Presentation] iPS細胞由来樹状細胞(iPSDCs)癌ワクチン療法の基礎研究の成果と臨床応用を見据えた今後の課題2016

    • Author(s)
      岩本博光
    • Organizer
      第116回日本外科学会定期学術集会
    • Place of Presentation
      大阪国際会議場
    • Year and Date
      2016-04-14
    • Related Report
      2016 Annual Research Report
  • [Presentation] 臨床応用に向けた腫瘍抗原(TAA)遺伝子導入iPS細胞由来樹状細胞(iPSDCs)癌 ワクチン療法の改善点2016

    • Author(s)
      岩本博光
    • Organizer
      第15回日本再生医療学会総会
    • Place of Presentation
      大阪国際会議場
    • Year and Date
      2016-03-17
    • Related Report
      2015 Annual Research Report
  • [Presentation] The cancer vaccine therapy using DCs derived from iPS cells (iPSDCs) expressing TAA gene2016

    • Author(s)
      岩本博光
    • Organizer
      2016 ASCO-GI
    • Place of Presentation
      サンフランシスコ、アメリカ
    • Year and Date
      2016-01-21
    • Related Report
      2015 Annual Research Report
    • Int'l Joint Research
  • [Presentation] iPS細胞由来樹状細胞(iPSDCs)癌ワクチン療法の基礎研究と臨床応用への道筋2015

    • Author(s)
      岩本博光
    • Organizer
      第53回日本癌治療学会学術総会
    • Place of Presentation
      京都国際会議場
    • Year and Date
      2015-10-29
    • Related Report
      2015 Annual Research Report

URL: 

Published: 2015-08-26   Modified: 2018-03-22  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi